Placebo Ezetimibe

DRUG2 trials

Sponsors

Baylor College of Medicine, Amgen

Conditions

HypercholesterolemiaPeripheral Arterial Disease

Phase 3

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

CompletedNCT02634580

AmgenHypercholesterolemia

Start: 2016-02-27End: 2018-05-26Updated: 2020-11-10

Phase 4

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

CompletedNCT00687076

Baylor College of MedicinePeripheral Arterial Disease

Start: 2004-04-30End: 2010-12-31Updated: 2020-02-06

Related Papers

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial

Journal of Atherosclerosis and Thrombosis2019-11-2028 citations

The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).

2013-10-1624 citations